SecBot SecBot

DNLI

Denali Therapeutics Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001714899 Biotech & Drug Discovery
$18.08 −0.66 (−3.52%)
Nov 16 4:00 PM ET · prev $18.74
Market cap
$3.0B
Mid cap
Consensus
Buy
92% Buy or better · 26 analysts
Median target
$35.00
+94% · range $24.00–46.00
1 year
+4.1%
from $17.37 · Nov 17
30 days
+0.2%
from $18.04
52-week range
$16.02–27.21
−34% from high · low Jan 5
Avg volume 20D
1.53M
Nov 4 spike 4.90M
Short interest
14.69M
≈9.2% of shares · −5.0%
Days to cover
9.9
at average volume
Insider net
−$435.3K
0 buyers · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $435.3K.

  • InstitutionsMIXED

    Q3 2026: 25 added (0 new), 17 trimmed or exited.

  • AnalystsBULLISH

    24 of 26 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.626 → −$0.618 over 90 days. 5 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −5.0% to 14.69M shares. 9.9 days to cover, ≈9.2% of shares.

  • TrendRANGE

    8% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Pictet Asset Management Holding SATRIM1,590,050$33.0M
MORGAN STANLEYADD1,371,479$28.3M
Nuveen, LLCADD854,682$17.7M
MARSHALL WACE, LLPADD803,420$16.6M
AMERICAN CENTURY COMPANIES INCTRIM461,575$9.5M
CITIGROUP INCTRIM332,788$6.9M
Hudson Bay Capital Management LPDOUBLED260,000$5.4M
ALPS ADVISORS INCADD211,772$4.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

26 analysts
Buy 92% rate it Buy or better
Strong Buy11Buy13Hold2Sell0Strong Sell0
12-month targets · 17 analysts

Price is below the lowest target. Median implies +94%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 13, 2026Wells Fargo
INITIATE
INITIATEOverweight
Nov 4, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 4, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Nov 4, 2026BTIG
REITERATE
REITERATEBuy
Aug 25, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$435.3K
sold · 3 insiders
DateInsiderTypeValue
Sep 4, 2026
Chin Peter Scott
Chief Medical Officer
Sep 4, 2026
SELL$36.9K
Sep 2, 2026
Thornberry Nancy
Director
Sep 2, 2026
SELL$14.6K
Sep 2, 2026
Thornberry Nancy
Director
Sep 2, 2026
SELL$247.3K
Sep 1, 2026
Schuth Alexander O.
COFO and Secretary
Sep 1, 2026
SELL$64.9K
Aug 12, 2026
Watts Ryan J.
President and CEO
Aug 12, 2026
GIFT32,220 sh
Aug 11, 2026
Schuth Alexander O.
COFO and Secretary
Aug 11, 2026
SELL$71.6K
Jun 3, 2026
BAKER BROS. ADVISORS LP
Director
Jun 3, 2026
AWARD19,226 sh
Jun 3, 2026
BAKER BROS. ADVISORS LP
Director
Jun 3, 2026
AWARD6,408 sh

Earnings setup

Estimates
−$0.62
EPS estimate, this quarter
+1%
estimate change, 90 days
5↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.62-$0.69–-$0.50+0.6%$32.6M
Next Q-$0.64-$0.69–-$0.58+7.6%$39.7M
Current FY-$2.00-$2.70–-$1.50+10.0%$53.9M
Next FY-$2.26-$2.66–-$1.50+6.7%$164.3M

Washington

Corporate Lobbying

9 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
14,694,882
shares short
-5.0%
vs prior settlement
9.9
days to cover
≈9.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 3, 2026 SEC
Denali reported Q3 2026 AVLAYAH net product revenue of $17.8M, accelerating from $3.6M in Q2, and guided Q4 2026…
8-K · Impact 6/10
Nov 3, 2026 SEC
Denali Therapeutics reported Q3 2026 AVLAYAH net product revenue of $17.8M, its second full commercial quarter, and…
PRESS-RELEASE · Impact 5/10
Nov 3, 2026 Earnings
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNL
Oct 30, 2026 Press
Denali Therapeutics announced that its FDA-approved drug AVLAYAH (tividenofusp alfa-eknm) received the 2026 Prix…
Impact 3/10
Sep 30, 2026 Inst.
Pictet Asset Management Holding · TRIM
1,590,050 shares ($33.0M)
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
1,371,479 shares ($28.3M)
Sep 4, 2026 Insider
Chin Peter Scott sold 1,654 shares
Chief Medical Officer @ $22.29 ($36.9K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

12 filings · 5 press releases · 3 bullish · 0 bearish · 2 mixed · 7 neutral
All DNLI filing & press-release reports (17)